News Zai Lab Limited

Stocks

ZLAB

US98887Q1040

Pharmaceuticals

Real-time Estimate Cboe BZX 15:35:57 2026-11-13 EST			5-day change	1st Jan Change
24.54 ^USD	-5.78%		-3.26%	+39.74%

09:05am	Zai Lab Limited - Special Call
07:28am	Zai Lab Says Experimental Drug Reduced Activity of Protein Linked to Atopic Dermatitis by at Least 90%	MT

All News

Mentions Relevance

993ddc82980.KtJOm1D3xbKN1nuBUqcv96_MTjJ2wsK5WwA5eoxoZYo.QpwrzweelNvIj03RPul8uOqEJQcbhqOBMVFQA9okUPlF5SHaHoKa-uGDSw

09:05am	Zai Lab Limited - Special Call
07:28am	Zai Lab Says Experimental Drug Reduced Activity of Protein Linked to Atopic Dermatitis by at Least 90%	MT
07:01am	Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing	BU
11-08	Zai Lab Limited announced that it has received $249.9336 million in funding from a group of investors	CI
11-06	Zai Lab Q3 Performance Meets Expectations With Pivotal 2027 Ahead, UBS Says	MT
11-05	Zai Lab Q3 Loss Widens, Revenue Declines	MT
11-05	Zai Lab Limited, Q3 2026 Earnings Call, Nov 05, 2026
11-05	Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas	BU
11-05	Zai Lab Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
11-05	Earnings Flash (ZLAB) Zai Lab Limited Reports Q3 Revenue $108.2M, vs. FactSet Est of $107.9M	MT
11-05	Earnings Flash (ZLAB) Zai Lab Limited Reports Q3 Revenue $108.2M, vs. FactSet Est of $107.9M	MT
11-05	Earnings Flash (ZLAB) Zai Lab Limited Reports Q3 Loss of $0.41 per ADS, vs. FactSet Est of $-0.58	MT
11-05	Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates	BU
10-26	Zai Lab Limited announced that it has received $249.9336 million in funding	CI
10-26	Zai Lab's Lung Cancer Drug Achieves Promising Response Rate in Phase 1b Trial; Shares up 4%	MT
10-23	Zai Lab Limited - Special Call
10-23	Zai Lab Says Zoci Plus Atezolizumab Improves Response Rate in Phase 1 Lung Cancer Trial	MT
10-23	Zai Lab Limited Shares First Data From Global Phase 1b Clinical Trial Evaluating Zocilurtatug Pelitecan In Combination With Atezolizumab With And Without Carboplatin As First-Line Treatment For Extensive-Stage Small Cell Lung Cancer	CI
10-23	Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer	BU
10-23	Zai Lab to Privately Place $250 Million in ADRs to Fund Drug Research	MT
10-22	Zai Lab to Raise $250 Million in Private Placement of ADSs	MT
10-22	Zai Lab Announces $250 Million Private Placement	BU
10-21	Zai Lab Limited announced that it expects to receive $249.9336 million in funding	CI
10-21	Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026	BU
10-14	Zai Lab Limited to Present Data from First Clinical Trial Evaluating ZL 1503, an Il-13/Il-31Ra Bispecific Antibody, for Atopic Diseases	CI